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Intravenous Infusion of the b3-Adrenergic Receptor Antagonist
APD418 Improves Left Ventricular Systolic Function in Dogs
With Systolic Heart Failure
HANI N. SABBAH, PhD, FHFSA,1 KEFEI ZHANG, MD,1 RAMESH C. GUPTA, PhD,1 JIANG XU, MD,1
VINITA SINGH-GUPTA, PhD,1 MICHAEL MA, MS,2 KATHE STAUBER, PhD,2 NATHALIE NGUYEN, PhD,2 AND
JOHN ADAMS, PhD2
Detroit, Michigan; and San Diego, California

ABSTRACT
Background: Unlike b1- and b2-adrenergic receptors (ARs), b3-AR stimulation inhibits cardiac contractility and relaxation. In the failing left ventricular (LV) myocardium, b3-ARs are upregulated, and can be
maladaptive in the setting of decompensation by contributing to LV dysfunction. This study examined the
effects of intravenous infusions of the b3-AR antagonist APD418 on cardiovascular function and safety in
dogs with systolic heart failure (HF).
Methods and Results: Three separate studies were performed in 21 dogs with coronary microembolization-induced HF (LV ejection fraction [LVEF] of approximately 35%). Studies 1 and 2 (n = 7 dogs each)
were APD418 dose escalation studies (dosing range, 0.3515.00 mg/kg/h) designed to identify an effective
dose of APD418 to be used in study 3. Study 3, the sustained efficacy study, (n = 7 dogs) was a 6-hour constant intravenous infusion of APD418 at a dose of 4.224 mg/kg (0.70 mg/kg/h) measuring key hemodynamic endpoints (e.g., EF, cardiac output, the time velocity integral of the mitral inflow velocity waveform
representing early filling to time-velocity integral representing left atrial contraction [Ei/Ai]). Studies 1 and
2 showed a dose-dependent increase of LVEF and Ei/Ai, the latter being an index of LV diastolic function.
In study 3, infusion of APD418 over 6 hours increased LVEF from 31 § 1% to 38 § 1% (P < .05) and
increased Ei/Ai from 3.4 § 0.4 to 4.9 § 0.5 (P < .05). Vehicle had no effect on the LVEF or Ei/Ai. In study
3, APD418 had no significant effects on the HR or the systemic blood pressure.
Conclusions: Intravenous infusions of APD418 in dogs with systolic HF elicit significant positive inotropic and lusitropic effects. These findings support the development of APD418 for the in-hospital treatment
of patients with an acute exacerbation of chronic HF. (J Cardiac Fail 2021;27:242252)
Key Words: Heart failure, left ventricular function, b-adrenergic receptors, b3-adrenergic receptors, positive inotropic and lusitropic agents.

b-Adrenergic receptors (ARs) belong to the superfamily
of membrane proteins known as G protein-coupled receptors. There are three recognized subtypes of b-ARs: b1ARs, b2-ARs, and b3-ARs. All three subtypes are expressed
in cardiomyocytes but possess distinct intracellular signaling.1 In the healthy heart, the b1-AR is the predominant subtype and comprises nearly 70% of the b-ARs in the heart,1,2
whereas b2-ARs contribute approximately 20% of total
b-ARs.2 b3-ARs are expressed at low levels in the healthy

heart and seem to have a minimal impact on cardiac contractile function.3,4 Stimulation of cardiac b1-AR elicits a
cyclic adenosine monophosphate- and calcium-dependent
increase in contractility and has direct chronotropic effects
via activation of pacemaker channels in the sinoatrial node
resulting in increased heart rate (HR).5,6 Selective stimulation of the b2-AR also enhances cardiac contractility; however, the mechanism by which this occurs is not fully
understood.7 In contrast, b3-ARs, activated by high concentrations of catecholamines, inhibit cardiac contraction and
relaxation and have no direct chronotropic effects.3,816
The intracellular signaling pathways modulated by the b3AR is an active area of research, but the negative inotropic
effects observed are thought to result from coupling to the
inhibitory G protein (Gi) and activation of the nitric oxide
(NO)cyclic guanosine monophosphate (cGMP) signaling
pathway, resulting in decreased myofilament sensitivity to
calcium.911,15
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A pivotal role for b-ARs in the progression of heart failure
(HF) is characterized by increased levels of circulating catecholamines resulting from sustained activation of the sympathetic nervous system which over time becomes harmful as
cardiac b-AR signaling becomes bioenergetically unfavorable and unresponsive owing to the downregulation and
desensitization of b1-ARs and b2-Ars.1,17,18 In contrast,
expression of cardiac b3-ARs is increased in several animal
models of HF9,19,20 and in the cardiomyocytes of patients
with both ischemic and nonischemic HF.13 Notably, b3-ARs
lack phosphorylation sites for the cyclic adenosine monophosphate-dependent protein kinase or b-adrenoceptor
kinase required for the receptor desensitization process,21
rendering them resistant to chronic catecholamine-induced
desensitization.22,23 In HF, increased b3-AR activation is
thought to serve as a protective mechanism to counterbalance
the excessive activation of b1/b2-AR by catecholamines. In
this context, myocardial b3-ARs are hypothesized to serve as
a physiological “brake” to suppress overstimulation of cardiac contractile function driven by sustained sympathetic
activity.15 Coordinated upregulation of the cardiac b3-AR
cognate G-protein subunit Gi in failing hearts18,24 would further facilitate b3-AR pathwaymediated suppression of cardiac contractile function. Experimental support for a direct
role of b3-AR in the failing heart comes from studies in dogs
with pacing-induced systolic HF. Increased levels of endogenous catecholamines with chronic pacing correlated with
depressed left ventricular (LV) contractility, and infusion of
L-748,337, a selective b3-AR antagonist, rapidly improved
LV contraction and relaxation.25 These findings suggest that
the acute blockade of b3-ARs can provide rapid relief of
depressed cardiac contractile function in systolic HF.
Acute cardiac decompensation in patients with HF with
reduced ejection fraction is a life-threatening condition
where novel and safe therapies aimed at increasing cardiac
contractility are needed. By selective inhibition of the b3AR, APD418 was designed to mitigate b3-ARmediated
cardiodepression, and rapidly improve hemodynamic status.
Furthermore, by targeting the selectively upregulated b3AR on cardiomyocytes, APD418 will enhance LV function
and avoid the potentially deleterious effect on the systemic
blood pressure or HR observed with current inotrope therapies. The objective of the present series of studies was to
determine the effects of intravenous (i.v.) administration of
APD418 on cardiovascular hemodynamic function in dogs
with systolic HF produced by multiple sequential intracoronary microembolizations.
Methods
Animal Model

The dog model of intracoronary microembolizationinduced systolic HF used in this study was previously
described.26 Twenty-one healthy, conditioned, class A
dealer mongrel dogs, weighing between 19.9 and 30.6 kg,
underwent serial intracoronary microembolizations performed 1 to 2 weeks apart, to produce HF. Coronary

microembolizations were performed during cardiac catheterization under general anesthesia and sterile conditions.
Embolizations were discontinued when the LV ejection
fraction (LVEF), determined angiographically, was approximately 35%. Dogs were induced using a combination of i.
v. injections of hydromorphone hydrochloride (0.22 mg/kg)
and acepromazine (0.100.22 mg/kg). The plane of anesthesia was maintained throughout the study using 1% to 2%
isoflurane. All dogs were maintained for at least 2 to 3
weeks after the last coronary microembolization before the
study protocol was initiated. The study was approved by the
Henry Ford Health System Institutional Animal Care and
Use Committee and conformed to the National Institute of
Health "Guide and Care for Use of Laboratory Animals"
(NIH publication No. 85-23).
Study Protocols

Three separate studies were performed to achieve the
desired objectives. All studies were performed under general anesthesia and sterile conditions as described elsewhere
in this article.
Study 1, Dose Escalation I. A total of 7 dogs with HF
were used in this study. All study measurements were performed during cardiac catheterization under general anesthesia and sterile conditions. After baseline hemodynamic,
ventriculographic and echocardiographic measurements,
vehicle (0.9% NaCl) was administered as a continuous constant i.v. infusion for 30 minutes. This was followed by 3
escalating doses of APD418 with each dose maintained for
30 minutes. The doses of APD418 were 1.4 mg/kg/h, 2.8
mg/kg/h, and 5.6 mg/kg/h. Doses were selected based on
pharmacokinetic modeling targeting estimated exposures.
At the end of each 30-minute infusion period, hemodynamic, ventriculographic, and echocardiographic measurements were taken. Venous blood samples were obtained at
baseline and at 30 minutes after each dose. Blood samples
were centrifuged at 3000 rpm for 10 minutes at 4 ˚C and
plasma withdrawn and placed in cryostorage tubes and
stored upright at 70 ˚C. Samples were used to determine
the plasma concentration of APD418.
Study 2, Dose Escalation II. The purpose of this study
was to identify a “no effect” dose of APD418 as well as a
maximal dose of APD418 beyond which no further clinically significant incremental effects could be elicited. After
baseline hemodynamic, ventriculographic, and echocardiographic measurements, APD418 or vehicle (5% dextrose;
pH = 5.0) was administered as a continuous constant i.v.
infusion. A total of 4 escalating doses of APD418 were
administered and each dose maintained for 60 minutes. The
doses of APD418 were 0.35 mg/kg/h, 5.6 mg/kg/h, 10.0
mg/kg/h, and 15.0 mg/kg/h. At the end of each 60-minute
period, complete hemodynamic, ventriculographic, echocardiographic and myocardial oxygen consumption
(MVO2) measurements were made. Venous blood samples
were obtained at baseline and at 60 minutes after each dose,
were centrifuged at 3000 rpm for 10 minutes at 4 ˚C and
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plasma extracted and placed in cryostorage tubes and stored
upright at 70 ˚C. Samples were used to determine plasma
concentration of APD418 and plasma levels of troponin-I
(Tn-I). Ultra-sensitive dog cardiac Tn-I was measured by
enzyme-linked immunosorbent assay using a commercially
available kit.
Study 3, Single Dose, 6-Hour Infusion. The purpose of
this study was to determine the temporal effects of a single
dose constant infusion of APD418 over the course of
6 hours. In this study, each dog received a 6-hour constant i.
v. infusion of APD418 (0.70 mg/kg/h) and a 6-hour constant
i.v. infusion of APD418 vehicle (0.9% NaCl) with each
infusion separated by at least 7 days. Hemodynamic, ventriculographic, echocardiographic, and MVO2 measurements
were made at pretreatment (baseline), before any drug or
vehicle infusion, and repeated at 1, 2, 4, and 6 hours after
initiating the infusions. Venous blood samples were
obtained at baseline and at 1, 2, 4, and 6 hours after initiating each infusion. Samples were centrifuged at 3000 rpm
for 10 minutes at 4 ˚C and plasma withdrawn and placed in
cryostorage tubes and stored upright at 70 ˚C. Samples
were used to determine plasma concentration of APD418.
Hemodynamic and Ventriculographic Measurements

All hemodynamic measurements were made during left
and right heart catheterizations in anesthetized dogs. Cardiac
catheterization was performed via a femoral artery and femoral vein approach. A 6F pigtail catheter and a 5F Swan-Ganz
catheter were advanced into the LV cavity and main pulmonary artery, respectively, under fluoroscopic guidance and
used to measure the phasic blood pressure. All data were
recorded on and analyzed using an analog-to-digital system
(Mennen Medical Ltd., Feasterville-Trevose, PA). The following parameters were evaluated in all dogs: (1) HR, (2)
aortic pressure (AoP), (3) LV end-diastolic pressure
(LVEDP), and (4) mean pulmonary artery pressure (mPAP).
Left ventriculograms were obtained with the dog placed on
its right side and recorded on digital media at 30 frames/s
during the injection of 20 mL of contrast material (ISOVUE300, Bracco Diagnostics, Inc., Princeton, NJ). Correction for
image magnification was made with a radiopaque calibrated
grid placed at the level of the left ventricle. LV end-systolic
volume (ESV)) and LV end-diastolic volume (EDV) were
calculated using the arealength method.27 Premature beats
and post-extra systolic beats were excluded from the analysis. The LVEF was calculated as the ratio of the difference of
EDV and ESV to EDV times 100. The stroke volume (SV)
was calculated as the difference between EDV and ESV. The
cardiac output (CO) was calculated as the product of SV and
HR. The systemic vascular resistance (SVR) was calculated
as previously described.28
Two-Dimensional Echocardiographic and Doppler
Measurements

Echocardiographic and Doppler studies were performed
using a Philips EPIC-7 ultrasound system in conjunction

with a Philips S5-1, 65 Hz, 10 cm transducer and recorded
on digital media for off-line analysis. LV fractional area of
shortening (FAS) was measured from 2-dimensional short
axis views as the difference between end-diastolic and endsystolic areas divided by end-diastolic area times 100.
Transmitral inflow velocity waveforms, measured using
pulsed-wave Doppler echocardiography, were used to calculate indexes of LV diastolic function, namely, (1) the
ratio of the mitral flow velocity integral during rapid early
LV filling (Ei) to the flow velocity integral during atrial
contraction (Ai), and (2) deceleration time of early mitral
inflow velocity (DCT).29
MVO2 Measurements

Measurements of MVO2 were made in studies 2 and 3 as
previously described.30 Coronary artery blood flow velocity
was measured using a Doppler flow velocity catheter (flow
wire) placed in the proximal segment of the circumflex coronary artery. Blood flow was estimated by calculating the
cross-sectional area of the circumflex coronary artery at the
site of the catheter tip using coronary arteriograms. MVO2
was determined as:
MVO2 = (Total coronary blood flow) £ (aorta to coronary
sinus O2 difference)
The oxygen content in the aorta and coronary sinus blood
were measured using an AVOXimeter 1000 (A-VOX Systems, Inc., San Antonio, TX).
Measurement of APD418 Plasma Concentration

A liquid chromatographytandem mass spectrometry
bioanalytical method for the determination of APD418 in
dog plasma (K2EDTA) was performed by Charles River
Lab (Montreal, Canada). Dog plasma samples were processed by protein precipitation, followed by dilution of the
supernatant. Then, 10-mL aliquots of the processed samples
were introduced for chromatographic separation using an
Ascentis Express C18 (2.7 mm, 4.6 £ 50 mm) column at a
mobile phase flow rate of 1.00 mL/min. A gradient LC
method was used. Mobile phase A was composed of
10 mM ammonium acetate:formic acid:trifluoroacetic acid
(100:0.1:0.025 v/v/v); and mobile phase B was composed
of methanol:formic acid:trifluoroacetic acid (100:0.1:0.025
v/v/v). Mass spectrometric detection was achieved with an
AB Sciex API-4000 in positive electronic ionization mode
using multiple reaction monitoring. The multiple reaction
monitoring transition for APD418 and internal standard
were 620 ! 253 and 625 ! 258, respectively. Quantification was performed using a linear regression (1/x2 weighting) analysis generated from the peak area ratio of the
analyte (APD418) over the internal standard (d5-APD418)
for the calibration standards. Reference standard APD418
mesylate was used for the preparation of calibration standards and QCs. The calibration curve ranges from 50.0 to
50,000.00 ng/mL.
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b3-AR Receptor Expression Study

Banked LV tissue from 7 normal dogs and 7 dogs with
microembolization-induced HF stored at 70 ˚C, was used
to confirm that LV tissue expression level of b3-ARs receptors was upregulated in dogs with coronary microembolization-induced HF. None of these dogs were treated with
APD418 and none received any HF therapies. The dogs,
however, were of similar age and sex as the study dogs and
those with HF had similar LVEF and duration of HF as the
study dogs. Messenger RNA (mRNA) expression of b3-AR
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(ADRB3: 50 -TTGGGTCTCATCATGGGCA-30 (Forward),
50 -GCACAGAAGACGGCGGAA-30 (Reverse); GAPDH:
50 -CCACTCCTCCACCTTTGAC-30 (Forward), 50 - ACCC
TGTTGCTGTAGCCA-30 (Reverse)) were measured in all
dogs using real-time PCR. Protein levels of b3-ARs (Novus
Biologicals, LLC, Centennial, CO; Cat# NBP1-00716) and
GAPDH (Fitzerald Industries International, Acton, MA,
Cat# 10R-G109A) were measured in SDS extracts of LV
tissue prepared from all dogs and subjected to Western blotting coupled with chemiluminescence detection and bands
were quantified in densitometric units.
Chemicals: APD418

APD418 was provided as a powder by Arena Pharmaceuticals (San Diego, CA). The vehicle solution was 0.9%
saline for studies 1 and 3, and 5% dextrose for study 2. The
infusion mixture of vehicle and APD418 was prepared
freshly just before daily administration.
Statistical Analysis

In all 3 studies, the primary LV systolic function endpoints
were LVEF, SV, and CO, and the primary LV diastolic function endpoints were Ei/Ai and DCT. Studies 1 and 2 were
designed as dose-ranging studies to identify a dose to be used
in study 3. Study 3 was designed as the primary outcome study.
Data analysis from study 3 was the analysis of primary interest.
Studies 1 and 2. Comparisons of hemodynamic, ventriculographic, echocardiographic, and Doppler measures
were conducted using repeated measures analysis of variance with the alpha set at 0.05. If significance was attained,
pairwise comparisons between baseline measures, vehicle
and APD418 measures were made using the StudentNewmanKeuls test with a P value of less than .05
considered significant.
Study 3. Temporal comparisons for each intervention
(vehicle or APD418) with respect to hemodynamic, ventriculographic, echocardiographic, and Doppler measures
were made using repeated measures analysis of variance
with the alpha set at 0.05. If significance was attained, pairwise comparisons between baseline measures and measures
at 1, 2, 4, and 6 hours were made using the StudentNewmanKeuls test with a P value of less than .05
considered significant. Comparisons of the treatment effect
change (difference between 6 hours and baseline for each

intervention) was made using unpaired t-test with a P value
of less than .05 considered significant. Comparisons
between normal dogs and dogs with HF with respect to
mRNA and protein b3-ARs levels were made using an
unpaired t-test with a P value of less than .05 considered
significant. Data from all studies are reported as mean §
standard error of the mean.
Results
All 21 dogs in all 3 studies completed their respective
protocols.
Regulation of b3-AR expression

The mRNA expression of b3-ARs normalized to GAPDH
was increased 3.1-fold in coronary microembolizationinduced HF dogs compared with normal dogs. Protein levels
of b3-ARs normalized to GAPDH were also markedly and
significantly increased (approximately 9-fold) in HF dogs
compared with normal dogs (2.053 § 0.175 vs 0.222 §
0.013; P < .05) (Fig. 1). These results confirm that b3-ARs
are significantly upregulated in dogs with coronary microembolization-induced HF compared with normal dogs.
Findings from Study 1: Preliminary Dose-Ranging Study

All hemodynamic, ventriculographic and echocardiographic/Doppler measures are shown in Table 1. When
compared with vehicle, APD418 has no significant effects
on HR, mean AoP (mAoP), or mPAP, and a modestly but
significantly lowered LVEDP. The LV EDV was essentially
unchanged during APD418 infusions, whereas the LV ESV
decreased significantly and the LVEF and FAS increased

Fig. 1. Expression of b3-adrenergic receptor (b3-AR) in hearts
from normal dogs and dogs with microembolization-induced heart
failure. Western blots showing b3-AR and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. Bar graph (mean §
standard error of the mean) shows the densitometric analysis of
b3-AR normalized to GAPDH in heart samples from failing dogs
(n = 7) compared with normal (NL) dogs (n = 7). P values are
based on unpaired t-test with a P value of less than .05 considered
significant.
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Table 1. Hemodynamic, Ventriculographic, Echocardiographic/Doppler Measurements Obtained at Baseline, at 30 Minutes After Vehicle
Infusion, and at 30 Minutes After Infusion of Each of Three Doses of APD418 (Study 1)

LV EDV (mL)
LV ESV (mL)
LVEF (%)
SV (mL)
CO (L/min)
HR (beats/min)
AoPsys (mm Hg)
AoPdias (mm Hg)
mAoP (mm Hg)
LVEDP (mm Hg)
SVR (dynes-s-cm5)
mPAP (mm Hg)
FAS (%)
Ei/Ai
DCT (msec)

Baseline

Vehicle

62 § 1
41 § 1
34 § 1
21 § 1
1.70 § 0.08
81 § 2
88 § 2
61 § 3
74 § 2
14 § 0.6
3525 § 257
16 § 0.7
34 § 1
3.1 § 0.1
98 § 6

63 § 1
41 § 1
35 § 1
22 § 1
1.81 § 0.07
83 § 1
92 § 2
68 § 3
79 § 3
15 § 0.6
3537 § 152
16 § 0.6
34 § 1
2.9 § 0.3
99 § 9

APD418 (1.4 mg/kg/h)

APD418 (2.8 mg/kg/h)

APD418 (5.6 mg/kg/h)

62 § 2
38 § 1*,y
38 § 1*,y
23 § 1*,y
1.94 § 0.11
83 § 1
92 § 3
67 § 4
79 § 4
14 § 0.8
3293 § 205
16 § 0.7
37 § 1*,y
3.6 § 0.3*,y
119 § 14

62 § 2
38 § 1*,y
39 § 1*,y
24 § 1*,y
2.02 § 0.08*,y
84 § 1*
91 § 4
67 § 5
79 § 5
13 § 0.8y
3118 § 183*,y
16 § 0.5
40 § 1*,y
3.7 § 0.3*,y
117 § 11

61 § 2
36 § 1*,y
41 § 1*,y
25 § 1*,y
2.14 § 0.08*,y
85 § 1*
90 § 3
66 § 5
77 § 4
12 § 1.0*,y
2895 § 153*,y
15 § 0.6
41 § 2*,y
4.3 § 0.4*,y
133 § 16*,y

AoPdias, diastolic aortic pressure; AoPsys, systolic aortic pressure; CO, cardiac output; DCT, deceleration time of the early rapid mitral inflow velocity
waveform; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; Ei/Ai, time velocity integral of the mitral inflow velocity waveform
representing early filling to time-velocity integral representing left atrial contraction; FAS, fractional area of shortening; HR, heart rate; LV, left ventricular;
mAoP, mean aortic pressure; mPAP, mean pulmonary artery pressure; LVEDP, left ventricular end-diastolic pressure; SV, stroke volume; SVR, systemic vascular resistance.
*P < .05 vs baseline.
y
P < .05 vs vehicle.

significantly in a dose-dependent manner, indicating an
improvement of LV systolic function. The improvement in
LVEF was accompanied by a dose-dependent increase in
SV and CO (Table 1 and Fig. 2A). Infusion of APD418
caused a dose-dependent decrease in the SVR that reached
significance at 2.8 mg/kg/h and 5.6 mg/kg/h. Furthermore,
the infusion of APD418 resulted in a dose-dependent
increase of Ei/Ai and DCT indicating improvement of LV
diastolic function (Fig. 2A). No signs of arrhythmias were
observed at any of the doses tested. The plasma samples at
the 30-minute time points were collected and analyzed
from each of the 7 dogs. The average dog plasma concentration results and statistics are summarized in Tables 2 and 3.
These results show that APD418 plasma concentrations
increased proportionately with an increased dose.

Findings from Study 2: Extension of the Dose-Ranging
Study

All hemodynamic, ventriculographic, echocardiographic,
and Doppler measures are shown in Table 4. At the lowest
dose of 0.35 mg/kg/h, APD418 had no significant effects on
the primary study end points of LVEF, CO, and Ei/Ai
(Fig. 2B). Compared with vehicle, this dose of APD418
also had no significant effects on LV ESV, SV, FAS, HR,
mAoP, LVEDP, mPAP, MVO2, or Tn-I (Table 4
and Fig. 2B). APD418 at this dose, however, modestly but
significantly decreased the SVR and increased the DCT.
These data suggest that the dose of 0.35 mg/kg/h of
APD418 is likely a no effect dose when viewed in terms of

Fig. 2. APD418 dose-dependently improves systolic and diastolic function in a canine model of microembolization-induced heart failure.
(A, B) Bar graphs (mean § standard error of the mean) depicting dose-dependent increase in cardiac function after a 30-minute (A) or 60minute (B) i.v. infusion of APD418. CO, cardiac output; DCT, deceleration time of mitral inflow velocity during early rapid LV filling; Ei/
Ai, ratio of the mitral inflow velocity integral during rapid early LV filling (Ei) to the flow velocity integral during atrial contraction (Ai);
HR, heart rate; LVEF, left ventricular ejection fraction; mAoP, mean aortic pressure; MVO2, myocardial oxygen consumption. P values are
based on a t-statistic for two means with a P value of less than .05 considered significant.

246
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on February 10, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

b3-Adrenergic Receptor Antagonist in Heart Failure  Sabbah et al 247
the mAoP. Further decrease in the mAoP were observed at
higher doses and accompanied by a small dose-dependent
increase in the HR that reached significance at 15 mg/kg/h
of APD418 compared with vehicle (Fig. 2B).
There was a significant dose-dependent increase in the
indexes of LV diastolic function, namely, Ei/Ai and DCT
(Fig. 2B). When compared with vehicle, the LVEDP did
not change significantly at any of the higher doses of
APD418 used. Compared with vehicle, the SVR decreased
significantly at all higher doses of APD418 used. There
were no significant differences in MVO2 or mPAP at any
dose tested. Plasma levels of Tn-I decreased significantly
compared with the vehicle level. There were essentially no
differences in the LV ESV, EF, CO, or FAS between
APD418 doses of 10.0 and 15.0 mg/kg/h suggesting that
these were the maximal effective doses, beyond which no
further LV functional benefits are likely to be elicited. No
signs of arrhythmias were observed at any dose tested.
Plasma samples at the 1-hour time points were collected
and analyzed from each of the 7 dogs. The average dog
plasma concentration results and statistics are summarized
in Table 2. These results show that APD418 plasma concentrations increased proportionately with the increased dose.

Table 2. Average Dog Plasma Concentrations Obtained at 30 or
60 Minutes After Infusion of Each Dose of APD418 (Studies 1 and
2)
Dose (mg/kg/h)

Plasma concentration (ng/mL)

Study 1 (30-min i.v. infusion of APD418)
1.4
747 § 21
2.8
1635 § 44
5.6
3478 § 58
Study 2 (60-min i.v. infusion of APD418)
0.35
252 § 15
5.6
3642 § 195
10.0
7454 § 390
15.0
12,178 § 648

N

%CV

7
7
7

7.5
7.1
4.4

7
7
7
7

15.6
14.2
13.9
14.1

CV, coefficient of variation.

Table 3. Average Dog Plasma Concentrations Obtained at 1, 2, 3,
4, 5, and 6 Hours After Initiating APD418 Infusion (Study 3*)
Time (h)

Plasma Concentration (ng/mL)

N

%CV

485 § 37
577 § 50
633 § 51
693 § 61
717 § 49
695 § 60

7
7
7
7
7
7

20.4
22.7
21.3
23.2
18.2
22.8

1
2
3
4
5
6

Plasma concentration is represented as mean § standard error of the mean.
Abbreviation as in Table 3.
*An i.v. infusion of APD418 at a constant dose of 0.70 mg/kg/h.

Findings From Study 3: Sustained Response and
Primary Outcome Study

the absence of significant changes in measures of LV systolic function.
Higher doses of APD418 had no effects on EDV, but significantly decreased the ESV and significantly increased the
LVEF, FAS, SV, and CO compared with vehicle (Table 4,
Fig. 2B). There were only modest improvements among the
3 highest doses, favoring the highest dose. At 5.6 mg/kg/h
and higher, there was a modest but significant decrease in

All hemodynamic, ventriculographic, echocardiographic,
and Doppler measures are shown in Table 5. Vehicle infusion over 6 hours had no significant effects on the HR,
LVEDP, mPAP, EDV, ESV, LVEF, CO, FAS, Ei/Ai, DCT,
or MVO2. The infusion of vehicle, however, caused modest
decreases in the AoP and SVR that reached statistical significance. Compared with pretreatment measures, treatment
with APD418 over 6 hours had no effects on the HR, EDV,

Table 4. Hemodynamic, Ventriculographic, and Echocardiographic/Doppler Measurements Obtained at Baseline, at 60 Minutes After
Vehicle Infusion, and at 60 Minutes After Infusion of Each Dose of APD418 (Study 2)

LV EDV (mL)
LV ESV (mL)
LVEF (%)
SV (mL)
CO (L/min)
HR (beats/min)
AoPsys (mm Hg)
AoPdias (mm Hg)
mAoP (mm Hg)
LVEDP (mm Hg)
SVR (dynes-s-cm5)
mPAP (mm Hg)
FAS (%)
Ei/Ai
DCT (msec)
MVO2 (mmol/min)
Tn-I (ng/mL)

Baseline

Vehicle

52 § 1
35 § 2
32 § 1
17 § 1
1.36 § 0.06
81 § 3
96 § 4
65 § 3
76 § 3
13 § 0.6
4527 § 138
16 § 0.5
33 § 1
3.5 § 0.5
123 § 8
131 § 22
0.36 § 0.03

52 § 1
35 § 2
33 § 2
17 § 1
1.38 § 0.05
81 § 2
92 § 4
62 § 3
73 § 3
13 § 0.4
4266 § 213
15 § 0.6
33 § 1
3.5 § 0.3
124 § 8
115 § 10
0.34 § 0.02

APD418
(0.35 mg/kg/h)

APD418
(5.6 mg/kg/h)

APD418
(10.0 mg/kg/h)

APD418
(15.0 mg/kg/h)

52 § 1
35 § 1
33 § 2
17 § 1
1.39 § 0.01
81 § 2
92 § 2
59 § 2*
70 § 3
12 § 0.5
4069 § 190*,y
15 § 0.8
34 § 1
4.0 § 0.5
136 § 7*,y
118 § 14
0.35 § 0.02

52 § 1
32 § 1*,y
38 § 2*,y
20 § 1*,y
1.62 § 0.08*,y
82 § 2
88 § 2*
53 § 1*,y
66 § 2*,y
11 § 0.5*
3292 § 139*,y
15 § 0.7
38 § 2*,y
4.7 § 0.4*,y
159 § 7*,y
115 § 12
0.18 § 0.02*,y

52 § 1
32 § 1*,y
39 § 2*,y
20 § 1*,y
1.72 § 0.10*,y
85 § 2
86 § 2*
52 § 2*,y
63 § 2*,y
11 § 0.7*
2981 § 131*,y
15 § 0.8
39 § 2*,y
5.5 § 0.7*,y
164 § 9*,y
110 § 10
0.18 § 0.02*,y

51 § 1
31 § 1*,y
39 § 2*,y
20 § 1*,y
1.72 § 0.10*,y
87 § 2*,y
86 § 2*
54 § 2*,y
63 § 2*,y
11 § 0.3*
2957 § 143*,y
15 § 0.9
38 § 2*,y
5.8 § 0.5*,y
175 § 8*,y
124 § 21
0.19 § 0.02*,y

MVO2, myocardial oxygen consumption; Tn-I, troponin-I. All other abbreviations as in Table 1.
*P < .05 vs baseline.
y
P < .05 vs vehicle.
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Table 5. Hemodynamic, Ventriculographic, Echocardiographic, and Doppler Measurements Obtained Before Treatment (Baseline) and at
1, 2, 4, and 6 Hours After Initiating Vehicle or APD418 Infusion (Study 3)
Before Treatment
Vehicle
LV EDV (mL)
LV ESV (mL)
LVEF (%)
SV (mL)
CO (L/min)
HR (beats/min)
AoPsys (mm Hg)
AoPdias (mm Hg)
mAoP (mm Hg)
LVEDP (mm Hg)
SVR (dynes-s-cm5)
mPAP (mm Hg)
FAS (%)
Ei/Ai
DCT (msec)
MVO2 (mmol/min)
APD418 (0.70 mg/kg/h)
LV EDV (mL)
LV ESV (mL)
LVEF (%)
SV (mL)
CO (L/min)
HR (beats/min)
AoPsys (mm Hg)
AoPdias (mm Hg)
mAoP (mm Hg)
LVEDP (mm Hg)
SVR (dynes-s-cm5)
mPAP (mm Hg)
FAS (%)
Ei/Ai
DCT (msec)
MVO2 (mmol/min)

1 Hour

2 Hours

4 Hours

6 Hours

57 § 5
39 § 3
32 § 1
18 § 1
1.47 § 0.13
82 § 2
94 § 2
63 § 1
75 § 1
13 § 1.0
4287 § 467
15 § 0.6
32 § 2
3.3 § 0.3
134 § 4
122 § 20

57 § 4
39 § 3
32 § 1
19 § 1
1.57 § 0.14
84 § 3
92 § 2*
60 § 1*
72 § 1*
13 § 0.8
3854 § 412*
14 § 0.5
32 § 1
3.5 § 0.4
139 § 3
114 § 17

57 § 5
39 § 3
32 § 1
18 § 2
1.47 § 0.14
80 § 2
90 § 3*
58 § 1*
70 § 1*
13 § 0.9
4045 § 453*
14 § 0.5
32 § 2
3.5 § 0.3
137 § 4
106 § 10

57 § 4
38 § 3
32 § 1
18 § 1
1.53 § 0.14
83 § 3
89 § 2*
56 § 2*
67 § 2*
12 § 0.7
3712 § 398*
14 § 0.4
32 § 1
3.4 § 0.4
138 § 5
116 § 16

56 § 4
38 § 3
32 § 1
18 § 1
1.49 § 0.13
82 § 2
88 § 2*
54 § 1*
66 § 1*
12 § 0.8
3755 § 408*
14 § 0.5
32 § 2
3.6 § 0.4
139 § 5
119 § 19

59 § 4
40 § 3
31 § 1
18 § 1
1.46 § 0.10
79 § 2
89 § 1
58 § 2
70 § 1
13 § 0.6
3948 § 317
14 § 0.5
32 § 1
3.4 § 0.4
119 § 7
138 § 17

59 § 4
40 § 3
33 § 1*
19 § 1*
1.48 § 0.10
77 § 2
92 § 2
63 § 3
74 § 3
14 § 0.6
4085 § 310
14 § 0.6
33 § 1
3.6 § 0.4
128 § 6
126 § 10

59 § 4
39 § 3
35 § 1*
21 § 1*
1.65 § 0.14*
80 § 2
91 § 1
61 § 2
71 § 2
12 § 0.7*
3585 § 292*
14 § 0.6
36 § 1*
3.9 § 0.5*
128 § 6
134 § 14

58 § 4
37 § 3
36 § 1*
21 § 1*
1.70 § 0.11*
82 § 2
89 § 1
59 § 2
70 § 1
11 § 0.7*
3368 § 261*
14 § 0.5
37 § 2*
4.4 § 0.5*
133 § 8*
145 § 13

59 § 4
37 § 3
38 § 1*
22 § 1*
1.77 § 0.12*
80 § 3
88 § 2
56 § 1
67 § 1
12 § 0.6*
3123 § 229*
14 § 0.5
38 § 2*
4.9 § 0.5*
144 § 8*
151 § 15

Abbreviations as in Tables 1 and 3.
*P < .05 vs before treatment.

performed and a significant positive linear correlation
between plasma concentration and improved LV function
was observed (R2 = 0.9187, P = .0415).

mAoP, mPAP, or MVO2 but decreased the LVEDP and
SVR in a time-dependent manner. Treatment with APD418
tended to decrease the ESV and significantly increase the
LVEF, FAS, SV, CO, Ei/Ai, and DCT in a time-dependent
manner when compared with pretreatment.
Comparisons of the treatment effect D defined as the difference between measures at 6 hours and measures at baseline for each intervention (ie, vehicle or APD418) are shown
in Table 6 and Fig. 3. There were no significant treatment
effect differences with respect to the HR, LVEDP, mPAP,
EDV, SVR, or MVO2. Compared with vehicle, treatment
with APD418 significantly increased the LVEF, CO, Ei/Ai,
and DCT (Fig. 3). Systolic blood pressure, diastolic blood
pressure, and mAoP were significantly higher during administration of APD418 compared with vehicle. These differences were driven primarily by the decrease in the AoP during
vehicle administration, as discussed elsewhere in this article.
No signs of arrhythmias were observed during the 6-hour
infusion of APD418. Six plasma samples obtained hourly
from 1 to 6 hours after dosing were analyzed for each dog.
The average plasma concentration results and statistics are
summarized in Table 3. Plasma concentrations correlated
well with improved LV function observed during the 6-hour
infusion with APD418 (Fig. 4). Correlation statistics were

Table 6. Comparison of Treatment Effect Change (Difference
Between 6 Hours and Before Treatment) for All Hemodynamic,
Ventriculographic, Echocardiographic, and DOPPLER Measures
Between Vehicle and APD418 (Study 3)

D LV EDV (mL)
D LV ESV (mL)
D LVEF (%)
SV (mL)
D CO (L/min)
D HR (beats/min)
D AoPsys (mm Hg)
D AoPdias (mm Hg)
D mAoP (mm Hg)
D LVEDP (mm Hg)
D SVR (dynes-s-cm5)
D mPAP (mm Hg)
D FAS (%)
D Ei/Ai
D DCT (ms)
D MVO2 (mmol/min)

Vehicle

APD418

P value

1.0 § 0.6
1.1 § 0.3
0.4 § 0.5
0.1 § 0.5
0.02 § 0.04
0.1 § 1.3
6.0 § 1.4
8.6 § 1.8
8.6 § 1.5
1.3 § 0.7
533 § 112
0.9 § 0.3
0.2 § 0.4
0.34 § 0.22
4.3 § 3.8
3 § 6

0.0 § 0.5
3.6 § 0.5
6.4 § 0.4
3.6 § 0.4
0.31 § 0.04
1.0 § 0.8
1.0 § 1.6
1.7 § 1.4
2.9 § 1.2
1.6 § 0.2
826 § 131
0.7 § 0.4
6.3 § 1.0
1.47 § 0.19
24.9 § 4.9
13 § 12

.225
.001
.0001
.0001
.0001
.570
.037
.011
.012
.688
.115
.696
.0001
.002
.006
.256

Abbreviations as in Tables 1 and 3. P values are comparisons between
vehicle and APD418 based on unpaired t-test.
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Fig. 3. Improvement in systolic and diastolic function with APD418 is sustained over a 6-hour treatment. (A) Bar graphs (mean § standard
error of the mean) depicting comparisons between treatment effect change between vehicle (black bars) and APD418 (grey bars) measures in
study 3. Abbreviations as in Fig. 2. P values are based on a t-statistic for two means with a P values of less than .05 considered significant.

Discussion

ventricular function with either acute or chronic treatment in
animal models of HF.20,25,33,34 Additionally, mice with
chronic b3-AR deficiency showed improved contractile

The objective of the present studies was to determine the
effects of i.v. administration of APD418 on cardiovascular
function in dogs with systolic HF caused by multiple sequential intracoronary microembolizations. APD418 binds with
high affinity to the human b3-AR (Ki = 8.2 nM) displaying
more than 400- to 600-fold selectivity over human b1-AR and
b2-AR, respectively (Thuy-Anh Tran, 2015). Similar functional potency and selectivity of APD418 was also observed
in Chinese Hamster Ovary cells expressing canine b3-AR
(Thuy-Anh Tran, 2015 and 2016). By comparison L-748,337,
a first-generation b3-AR antagonist, binds with high affinity
to the human b3-AR (Ki = 4.0 nM), but is only 90-fold and
45-fold selective over b1-AR and b2-AR, respectively.31
Despite its suboptimal selectivity, acute i.v. administration of
L-748,337 was shown to improve LV contraction and relaxation in a canine model of pacing-induced HF.25 Further clinical development of this compound has not been pursued.
SR59230A is another well-characterized compound previously described as a b3-AR antagonist and commonly used in
animal studies. However, further development has been hampered owing to its lack of selectivity for the human b3AR.31,32 Despite their limitations, first-generation b3-AR
antagonists have been shown to improve LV and right

Fig. 4. Improvement in cardiac performance with APD418 correlates with plasma concentrations. Bar graph (mean § standard error
of the mean [SEM]) showing increase in left ventricular ejection
fraction during a 6-hour i.v. infusion with continuous APD418 treatment (grey bars) and its correlation with increased plasma concentrations during the same period of time (line graph; mean § SEM).
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response to isoproterenol12 and preserved myocyte function in
a mouse model of isoproterenol-induced HF.35 The potential
therapeutic role of targeted b3-AR modulation in acute and
chronic HF is still being evaluated experimentally and clinically. However, our current approach was designed to evaluate the role of b3-AR antagonism as an acute treatment in
animals with systolic HF.
In isolated LV cardiomyocytes from dogs with rapid pacing-induced HF, stimulation with the selective b3-AR agonist BRL-37344 significantly decreased the cardiomyocyte
contraction index dL/dtmax from 67.2 to 49.7 mm/s and significantly decreased the cardiomyocyte relengthening
index, dR/dtmax, from 53.3 to 40.5 mm/s (36). This BRL37344induced negative inotropic response was abolished
by pretreatment with APD418 (5 £ 106 M).36 These data
indicate that APD418 is a b3-AR antagonist/blocker. The
direct negative inotropic effect of b3-AR agonism on cardiac myocytes was confirmed in a recent study using human
ventricular trabeculae from patients with HF with reduced
ejection fraction, in which BRL-37344 at a concentration of
0.1 mM, significantly decreased the force of contraction by
nearly 20%.37 In this same study, inhibition of the b3ARmediated negative inotropy with APD418 at a concentration of 10 nM potentiated the force of contraction
induced by norepinephrine by nearly 20%.37 Our unpublished human receptor binding data strongly suggest that, at
these concentrations, APD418 is not expected to interact
with any other AR than b3-AR. These data provide further
support that APD418 is an antagonist of the b3-AR. In other
studies, acute i.v. administration of APD418 to dogs with
normal heart function (prepacing) did not affect cardiac
function (using LV end systolic pressurevolume relationship). However, after 4 weeks of pacing-induced HF,
APD418 was administered and significantly improved cardiac performance in the same animals without changes in
the HR or blood pressure.36 Finally, previous studies also
showed that L-748,337, another selective b3-AR antagonist,
prevented the b3-ARmediated negative inotropy in dogs
with pacing-induced HF, supporting further the beneficial
effect of selectively blocking b3-AR in HF9,25 and are consistent with the present study results using APD418.
In the present study, a highly validated canine model of
microembolization-induced systolic HF was used to simulate
HF with reduced ejection fraction in humans.3842 In both
microembolization and pacing-induced canine models of HF,
high levels of circulating catecholamines have been
observed25,26 and LV b3-AR expression level is increased9
(Fig. 1), recapitulating key observations found in LV myocardium of humans with HF.13 In contrast with pacing-induced
HF whereby LV functional recovery can occur slowly upon
the cessation of rapid pacing, coronary microembolization
leads to irreversible myocardial injury with slow progressive
worsening of LV dysfunction, as seen in the human disease
counterpart.26,43 Two dose escalation protocols were conducted to delineate the subtherapeutic and maximum effect
doses of APD418. At the lowest APD418 dose of 0.35 mg/kg/h,
no significant improvement in measures of LV systolic

function was observed suggesting that this may represent a no
effect dose, at least from the perspective of LV systolic function. Higher doses starting at 1.4 mg/kg/h resulted in significant dose-dependent improvements in LV systolic and
diastolic function, with further improvements observed up to
5.6 mg/kg/h. No further increases in cardiac function were
observed above 10 mg/kg/h; however, a modest but significant
decrease in the mAoP was observed at 5.6 mg/kg/h, with
further decreases seen at higher doses. It is possible that, at
these supratherapeutic doses of APD418, high plasma drug
concentration results in the nonselective inhibition of b1/b2ARs causing a reduction of mAoP accompanied by a reflex
increase in the HR. At doses between 1.4 mg/kg/h and less
than 5.6 mg/kg/h, APD418 infusion improved the LV systolic
and diastolic function and was devoid of any chronotropic
effects, systemic blood pressurelowering effects, proarrhythmic effects, or increases in MVO2 and plasma Tn-I. The
absence of these undesirable effects at these doses are most
likely owing to the selective blockade of the b3-AR signaling
pathway, which mainly involves modulation of the
NOcGMPPKG signaling cascade, and does not directly
alter cyclic adenosine monophosphate and intracellular Ca2+
levels, unlike conventional inotropic agents.44 Numerous studies from multiple investigators have demonstrated that stimulation of b3-AR activate GiNOcGMPPKG signaling
pathway in the heart to induce a negative inotropic
effect.10,12,45,46 In fact, a previous study showed that blockade
of NO synthase (with L-NAME) or Gi signaling (with pertussis
toxin) inhibited a b3-ARmediated negative effect on the contractile function of cardiomyocytes isolated from dogs with
pacing-induced HF.9 Future mechanistic studies are planned
in cardiomyocytes isolated from the heart of dogs with normal
and decompensated heart function to confirm that APD418
inhibits the GiNOcGMPPKG signaling pathway in
cardiomyocytes.
The primary translational finding of the present study is
the sustained improvement in LV function seen during
6 hours of continuous infusion with APD418. Improved LV
systolic and diastolic function were evidenced by an
improvement in the indexes of LV systolic function,
namely, LVEF and CO, as well as an improvement in the
indexes of LV diastolic function, namely, Ei/Ai and DCT.
This sustained effect correlated directly with the pharmacokinetic profile of i.v. APD418 infusion and suggests that
continuous b3-AR blockade provides sustained hemodynamic benefits. During the 6-hour infusion of APD418, no
change in HR or mAoP were observed, indicating that
APD418 does not act as a direct vasodilator and the
decreased SVR observed in the dose-ranging studies is
likely a compensatory response to a stable mAoP in the
presence of a significant increase in CO. A significant
decrease in mAoP and SVR was observed during vehicle
infusion, but this result was most likely associated with the
exposure to anesthesia during a 6-hour period. Despite the
observed decrease in mAoP and SVR with vehicle, treatment with APD418 still resulted in significant improvements in cardiac function.
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In chronic HF, b3-AR upregulation and activation induce a
negative inotropic effect that serves as a protective mechanism
in response to the increased level of catecholamines. This
physiological brake is an adaptive mechanism that potentially
compensates for the sustained sympathetic overdrive.15
Accordingly, other groups have proposed the use of b3-AR
agonists as a potential treatment for chronic HF. To date, the
selective b3-AR agonist (mirabegron), when evaluated in a
small trial of patients with systolic HF (BEAT-HF) showed no
improvement of LV function after 6 months of therapy.47
However, patients with a baseline LVEF of less than 35% did
show a positive treatment effect. In contrast with chronic HF,
in patients with acute decompensated HF, the upregulated b3ARmediated negative inotropic effect may be maladaptive,
causing further contractile depression and exacerbating existing LV systolic dysfunction. Therefore, in this acute setting,
removing the b3-AR brake via selective inhibition with
APD418, and remediating depressed contractile function could
provide rapid hemodynamic improvement and promote cardiovascular and clinical recovery.
There are some limitations to the present study that merit
consideration. Given the mechanism of action of APD418,
this translational preclinical study was designed to primarily
examine the short-term effects of APD418 on systolic LV
function and not diastolic function. In retrospect, a more thorough analysis of LV diastolic function with measures such as
pressurevolume relationships and measurements of longitudinal and radial strain would have been useful to better and
more fully describe changes in LV diastolic function resulting
from use of i.v. APD418. Another important limitation is the
absence of data showing that APD418 actually targets downstream b3-AR linked pathways. Such data would confirm that
APD418 acts to increase contractility via inhibition of
GiNOcGMPPKG signaling pathway in cardiomyocytes.
Finally, the results of the present series of studies, when
viewed in concert, validate the rationale for advancing
APD418 into clinical development and suggest b3-AR
antagonists as a promising therapeutic approach for the
treatment of patients with acute systolic HF.
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